No profile data available.
Nektar Therapeutics (NKTR) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in San Francisco, United States, with about 63 full-time employees.
It reported revenue of $55.23 million for fiscal year 2025, down 43.9% from fiscal year 2024, and net income of -$164.08 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $10.13 million, down 9.3% from a year before. Its market capitalization was $1.41 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
Nektar Therapeutics reported $55.23 million in revenue for fiscal year 2025, down 43.9% from $98.43 million in fiscal year 2024. In Q2 2026 revenue was $10.13 million.
$1.41 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include ANI Pharmaceuticals, Inc. (ANIP), Ocular Therapeutix, Inc. (OCUL), Immunocore Holdings plc (IMCR), Sana Biotechnology, Inc. (SANA).